Sarepta Therapeutics | SRPT

Sarepta Therapeutics traded at $131.38 this Monday March 20th, increasing $8.69 or 7.08 percent since the previous trading session. Looking back, over the last four weeks, Sarepta Therapeutics gained 7.77 percent. Over the last 12 months, its price rose by 62.26 percent. Looking ahead, we forecast Sarepta Therapeutics to be priced at 118.79 by the end of this quarter and at 107.81 in one year, according to Trading Economics global macro models projections and analysts expectations.

Stock Price
131.38
Daily Change
7.08%
Yearly
62.26%

Ok
Trading Economics members can view, download and compare data from nearly 200 countries, including more than 20 million economic indicators, exchange rates, government bond yields, stock indexes and commodity prices.

The Trading Economics Application Programming Interface (API) provides direct access to our data. It allows API clients to download millions of rows of historical data, to query our real-time economic calendar, subscribe to updates and receive quotes for currencies, commodities, stocks and bonds.

API Features Documentation Interested? Click here to contact us
Please Paste this Code in your Website
width
height
 Preview
Peers Price Day Year
Daiichi Sankyo 4,489.00 -90.00 -1.97% 85.61%
Acadia Pharmaceuticals 19.76 -0.04 -0.20% -22.66%
Agios Pharmaceuticals 22.73 -0.53 -2.28% -20.33%
Alnylam Pharmaceuticals 187.52 2.07 1.12% 15.45%
Amgen 234.72 4.93 2.15% -0.68%
Avrobio Inc 1.23 0.04 3.36% -22.15%
BioCryst Pharmaceuticals 8.01 -0.09 -1.11% -49.24%
Biogen 267.91 4.75 1.81% 29.54%
Bluebird Bio 4.47 -0.07 -1.54% -7.07%
BioMarin Pharmaceutical 92.34 0.67 0.73% 13.78%
Capricor Therapeutics 4.48 0.14 3.23% -5.49%
Esperion Therapeutics 1.54 -0.01 -0.65% -72.15%
Gilead Sciences 79.46 2.15 2.78% 33.19%
Intercept Pharmaceuticals 15.04 -0.23 -1.51% -8.63%
Incyte Corp 74.22 0.60 0.82% -3.08%
Insmed 17.02 -0.40 -2.30% -26.48%
Ionis Pharmaceuticals 35.60 0.42 1.19% 1.95%
Eli Lilly 333.60 4.42 1.34% 15.18%
Moderna Inc 154.52 4.50 3.00% -11.89%
Mirati Therapeutics 40.53 -0.87 -2.10% -51.22%
Neurocrine Biosciences 97.21 2.96 3.14% 3.24%
Nektar Therapeutics 0.93 -0.05 -4.98% -83.63%
Lumos Pharma Inc. 3.16 -0.41 -11.48% -67.69%
Novavax 5.98 0.03 0.50% -92.39%
Pfizer 40.81 0.71 1.77% -24.69%
PTC Therapeutics 48.49 1.19 2.52% 32.49%
Ultragenyx Pharmaceutical 39.00 0.47 1.22% -43.30%
Regeneron Pharmaceuticals 759.25 11.60 1.55% 9.53%
Roche Holding 261.45 -0.30 -0.11% -28.79%
Sanofi 89.46 -0.34 -0.38% -4.12%
Sangamo BioSciences 1.93 -0.08 -3.98% -66.61%
Sarepta Therapeutics 131.38 8.69 7.08% 62.26%
Vertex Pharmaceuticals 298.95 3.18 1.08% 19.46%

Indexes Price Day Year
USND 11676 45.03 0.39% -15.63%
US2000 1745 19.10 1.11% -15.54%

Sarepta Therapeutics
Sarepta Therapeutics, Inc. is a commercial-stage biopharmaceutical company. The Company is focused on the discovery and development of ribonucleic acid (RNA)-targeted therapeutics, gene therapy and other genetic therapeutic modalities for the treatment of rare diseases. It is developing therapeutic candidates for a range of diseases and disorders, including Duchenne muscular dystrophy (DMD), Limb-girdle muscular dystrophies (LGMDs) and other neuromuscular and central nervous system (CNS) related disorders. Its commercial products, EXONDYS 51 (eteplirsen) Injection, VYONDYS 53 (golodirsen) Injection and AMONDYS 45 (casimersen) Injection is for the treatment of DMD in patients, who have a confirmed mutation of the DMD gene that is amenable to exon 51, exon 53 and exon 45 skipping. It is also developing gene therapy programs for various forms of LGMDs. Its LGMD product candidate, SRP-9003, is designed to transfer a gene that codes for and restores beta-sarcoglycan protein.